Scailyte develops ScaiVision, an AI-powered single-cell omics data analysis platform that analyzes millions of individual cells to identify precise molecular biomarker profiles and link them to clinical outcomes. The ETH spinoff, founded in 2017 and based in Basel, focuses on accelerating drug development and improving clinical trial and personalized cancer‑therapy success rates through multimodal biomarker discovery. ScaiVision has been tested in clinical settings including CAR‑T cell therapies and projects in endometriosis and solid tumors. Strategic partners such as Nilogen, Volv Global and Sirona DX collaborate with Scailyte to advance personalized therapies against cancers and rare diseases. The company recently raised new funding to expand U.S. partnerships in immuno‑oncology and further develop its biomarker technology. Leadership reports growing commercial traction and validation of market need from small patient‑population studies. Scailyte combines single-cell technologies, high-quality datasets and machine learning methods to identify disease-specific biomarkers with a focus on oncology and immunology. Its data analysis platform, ScaiVision, associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints such as diagnosis, progression, severity and treatment response to identify ultra-sensitive biomarker signatures. The company is led by Founder & CEO Dr. Peter Nestorov and is a spin-off of ETH Zurich based in Basel, Switzerland. In a Series A round the company raised CHF6M. The funding round was led by a Swiss family office, Mirabaud bank and existing backers. Scailyte said it will use the proceeds to accelerate growth, expand operations and broaden its business reach. Scailyte is a digital health company that discovers ultrasensitive biomarkers and develops in-vitro diagnostics (IVD) using single-cell technologies and its proprietary data analysis platform, ScaiVision. ScaiVision processes and interprets single-cell proteomics data (mass and flow cytometry) and includes core functionality for analysing single-cell transcriptomics data. The company is advancing assays in the rapidly emerging single-cell data technology field and aims to enable clinical applications of single-cell data. Scailyte plans to build upon its biomarker and IVD pipeline and to develop first clinical applications using single-cell biomarkers. Its pipeline includes biomarker candidates for endometriosis and CTCL, each with a market potential of several hundred million Francs, according to the company. Scailyte completed a pre-series A financing round, raising CHF3.7 million to accelerate development of assays, its biomarker and IVD pipeline, and clinical applications. Scailyte builds artificial intelligence–based software, marketed as ScaiVision, to analyze complex single-cell data for biomedical research, pharmaceutical discovery and precision diagnostics. The company also offers biomarker discovery services to complement customers' analyses with a single-cell perspective. ScaiVision was scheduled for commercial launch at the beginning of 2019 and the company intends to use new funding to accelerate its development and market entry. Scailyte has begun its first clinical study and is negotiating biomarker-discovery engagements with leading blue-chip companies. Founded in June 2017 and led by CEO Peter Nestorov, the company is based in Luzern, Switzerland. The recent seed financing provides resources to make ScaiVision more accessible and attractive to a wider range of customers.

Total raised

$21M

Funding rounds

4

Latest round

Series A

Latest activity

Dec 2023